Division of Abbott Laboratories Inc.
Latest From Evalve Inc.
The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.
Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed sum.
This month we profile CoolSpine and its catheter-based hypothermia device, Inseal Medical and its large-bore vascular closure device, and MitrAssist Medical, which is developing a valve-in-valve approach to treating mitral regurgitation.
Just as people improve their vision by wearing glasses or contact lenses instead of repairing or replacing their eyes, a mitral valve prosthesis from Israeli-based MitrAssist Medical Ltd. neither repairs nor replaces damaged mitral valves in the heart, but rather it augments and enhances native valve function. The company’s implant is placed on top of the native valve and anchored securely. This “valve-in-valve” approach is designed to prevent leakage and restore normal blood flow.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
Ferolyn Powell, Pres. & CEO
Doug Hughes, CFO
Troy Thornton, VP, R&D
Sean Cleary, SVP, Worldwide Sales & Mktg.
- Contact Info
Phone: (650) 330-8100
4045 Campbell Ave.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.